181.21
-1.73(-0.95%)
Currency In USD
| Previous Close | 182.94 |
| Open | 183.35 |
| Day High | 186.47 |
| Day Low | 180.4 |
| 52-Week High | 191.5 |
| 52-Week Low | 86.99 |
| Volume | 363,915 |
| Average Volume | 643,380 |
| Market Cap | 9.14B |
| PE | -38.8 |
| EPS | -4.67 |
| Moving Average 50 Days | 168.89 |
| Moving Average 200 Days | 130.28 |
| Change | -1.73 |
If you invested $1000 in Axsome Therapeutics, Inc. (AXSM) 10 years ago, it would be worth $21,964.85 as of February 15, 2026 at a share price of $181.21. Whereas If you bought $1000 worth of Axsome Therapeutics, Inc. (AXSM) shares 5 years ago, it would be worth $2,425.51 as of February 15, 2026 at a share price of $181.21.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23
GlobeNewswire Inc.
Jan 27, 2026 12:00 PM GMT
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
GlobeNewswire Inc.
Jan 15, 2026 12:00 PM GMT
NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced the first patient has been dosed in the
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue
GlobeNewswire Inc.
Jan 12, 2026 12:00 PM GMT
Total preliminary 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% annual growth, respectively AUVELITY® preliminary 4Q and full year 2025 net product sales of $155.1 million and